Thrivent Financial for Lutherans Has $3.98 Million Stake in Edwards Lifesciences Corporation $EW

Thrivent Financial for Lutherans raised its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 24.6% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 50,857 shares of the medical research company’s stock after acquiring an additional 10,045 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Edwards Lifesciences were worth $3,978,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Norges Bank bought a new position in Edwards Lifesciences during the second quarter valued at about $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in shares of Edwards Lifesciences by 111.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after acquiring an additional 4,805,819 shares during the period. Marshall Wace LLP increased its position in shares of Edwards Lifesciences by 127.5% during the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after purchasing an additional 3,864,908 shares during the period. Jennison Associates LLC raised its stake in shares of Edwards Lifesciences by 15.7% in the second quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock valued at $912,788,000 after purchasing an additional 1,584,958 shares in the last quarter. Finally, Holocene Advisors LP raised its stake in shares of Edwards Lifesciences by 35.2% in the second quarter. Holocene Advisors LP now owns 4,703,977 shares of the medical research company’s stock valued at $367,898,000 after purchasing an additional 1,223,460 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the sale, the vice president directly owned 38,970 shares in the company, valued at approximately $3,264,127.20. This represents a 22.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 45,465 shares of company stock valued at $3,804,610. 1.29% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on EW. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, October 8th. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $90.00 to $100.00 in a research report on Thursday. BTIG Research reaffirmed a “buy” rating and set a $103.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Thursday, December 4th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $93.95.

Edwards Lifesciences Price Performance

NYSE:EW opened at $85.66 on Friday. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The firm has a market cap of $49.71 billion, a PE ratio of 36.92, a price-to-earnings-growth ratio of 3.85 and a beta of 0.97. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The company’s 50-day moving average price is $82.53 and its two-hundred day moving average price is $79.28.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.